Global Telmisartan Market - 2022-2029

Global Telmisartan Market - 2022-2029

Market Overview

The global telmisartan market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX% during the forecast period (2022-2029).

Telmisartan drug is a non-peptide angiotensin receptor blocker (ARB) used to treat hypertension and lower the risk of cardiovascular disease. Telmisartan can be taken on its own or combined with other medications like hydrochlorothiazide and amlodipine. Telmisartan comes in three different strengths: 20 mg, 40 mg, and 80 mg tablets. Telmisartan is a drug that is used to treat mild to moderate hypertension. It works by allowing blood to flow more freely by relaxing blood vessels.

Market Dynamics

In the coming years, the global telmisartan market is expected to expand. Factors driving market growth include an increase in the prevalence of high blood pressure, an increase in the incidence of chronic diseases such as diabetes, an increase in the geriatric population, and others. On the other hand, an increase in the approval of abbreviated new drug applications (ANDA) to manufacture generic telmisartan tablets is expected to provide growth opportunities in the telmisartan market.

An increase in the prevalence of high blood pressure (hypertension) will drive the market growth

Factors expected to drive the market growth include an increase in the prevalence of high blood pressure (hypertension), an increase in the geriatric population, and government initiatives to raise awareness about blood pressure diseases. For example, in May 2017, the Argentinian Society of Hypertension (SAHA) participated in campaigns such as 'May Measurement Month & World Hypertension Day' to raise public awareness about hypertension and its management. Furthermore, an increase in marketing approvals for generic versions of telmisartan, an increase in sedentary lifestyle, and an increase in the incidences of chronic diseases such as diabetes and kidney disease are expected to drive telmisartan market growth.

Furthermore, The Texas Council on Stroke and Cardiovascular Disease collaborate with key stakeholders to implement a plan to lower the burden of cardiovascular disease and stroke burden in Texas. The plan includes an overview of the current state of cardiovascular disease and stroke in Texas, a summary of the findings from the heart disease and stroke prevention system assessment, and data on mortality, morbidity, prevalence, and risk factors.

Furthermore, rising marketing approvals for generic versions of telmisartan are expected to drive the telmisartan market forward. For example, Zydus Cadila received FDA approval in August 2017 to market telmisartan and hydrochlorothiazide tablets in strengths of 40mg/12.5 mg, 80mg/12.5 mg, and 80mg/25 mg.These factors are driving the growth of telmisartan market.

Shortage of the drug is likely to hamper the market growth

However, drug shortages are likely to stifle the growth of the Telmisartan market. For example, the US FDA reported a shortage of Boehringer Ingelheim Pharmaceuticals, Inc.'s telmisartan and amlodipine (Twynsta) tablets 80mg/10mg, 30 count blister in June 2018 due to the company's business discontinuation. Furthermore, Drug Shortages Canada reported a shortage of Teva- Telmisartan 80mg tablets in Canada due to a failure to follow good manufacturing practices.

COVID-19 Impact Analysis

On January 30, 2020, the World Health Organization (WHO) declared the COVID-19 outbreak a public health emergency of international concern. COVID-19 has affected approximately 210 countries worldwide. Telmisartan tablet manufacturing and distribution companies have been impacted to a limited extent by COVID-19, owing to shutdowns in various COVID-19 affected countries and an increase in the number of healthcare workers falling ill as a result of the COVID-19 pandemic, resulting in a supply shortage.

Segment Analysis

The hypertension segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

Currently, hypertension is a major revenue contributor based on indication, and it is expected to grow significantly during the forecast period. Increased prevalence of hypertension, increased demand for antihypertensive drugs, and increased awareness about hypertension and its management through global level campaigns contribute to the market's growth. Furthermore, the availability of better treatment options for hypertension, an increase in the number of product approvals, and an increase in the geriatric population suffering from hypertension are the other factors driving the market growth.

Telmisartan is a medication that inhibits the angiotensin II receptor (ARB). It works by preventing the body from producing a substance that causes blood vessels to constrict. Telmisartan relaxes the blood vessels as a result. This lowers blood pressure while increasing blood and oxygen supply to the heart. According to the World Health Organization (WHO) 2021, across the world, an estimated 1.28 billion adults aged 30-79 years have hypertension, with the majority (two-thirds) living in low- and middle-income countries.An estimated 46% of adults with hypertension are unaware of their condition.Only 42 percent of adults with hypertension are diagnosed and treated.One in every five adults (21 percent) has hypertension under control.Worldwide, hypertension is a leading cause of death.One of the global non-communicable disease targets is to reduce hypertension prevalence by 33% between 2010 and 2030.People are now more aware about the blood related diseases leading to the boost in the telmisartan market.

Geographical Analysis

North America region holds the largest market share of the global telmisartan market

North America is anticipated to dominate the telmisartan market, globally. The factors attributed to the high growth of the region are the increase in the number of hypertension patients in emerging economies, an increase in the use of antihypertensive drugs, the development of the R&D sector, an increase in healthcare reforms, and technological advances in pharmaceutical drug manufacturing. Furthermore, an increase in demand for telmisartan tablets, funding from government and non-government sectors to raise awareness about hypertension and cardiovascular diseases, an increase in the number of hospital pharmacies and online pharmacies, and the presence of a large population base all contribute to market growth.

In addition, organic and inorganic strategies such as mergers and acquisitions and partnerships within key market players will strengthen their product portfolio in the studied market which will drive the market. Also, several product launches in the market will lead to lucrative growth of the market. For instance, in June 2020, Cipla has collaborated with Boehringer Ingelheim India. The companies hoped to co-market three new oral anti-diabetics drugs under this collaboration: Oboravo (Empagliflozin), Oboravo Met (Empagliflozin+Metformin), and Tiptengio (Empagliflozin+Linagliptin). Empagliflozin is approved for glucose control in type 2 diabetes patients; it is also approved to reduce the risk of cardiovascular death in type 2 diabetes patients with cardiovascular disease. These factors are likely to drive the market growth in North America.

Competitive Landscape

The telmisartan Market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Abbott Laboratories, Aurobindo Pharmaceuticals, Boehringer , Cipla Inc, GlaxoSmithKline Plc, Mylan N.V.,Sanofi, Sun Pharmaceuticals, Teva Pharmaceuticals, Zydus Cadila, Solco Healthcare, Jubliant Cadista, Macleods Pharmaceutical, Torrent Pharmaceutical among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the telmisartan market globally. For instance, In Feb 2019, Cipla formed a joint venture with Wellthy Therapeutics Private Limited. The collaboration aimed to provide a combination of pharmacotherapy and digital therapeutics for improved patient outcomes in diabetology and chronic cardiology therapies.

Key Developments

In Feb 2019, In the United States, Teva Pharmaceutical introduced ALYQ, a generic version of ADCIRCA1 (tadalafil) tablets, 20 mg. It is a phosphodiesterase 5 (PDE5) inhibitor that has been recommended for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity.

In October 2018, The US Food and Drug Administration approved Boehringer Ingelheim's SEMINTRA 10 mg/mL oral solution. SEMINTRA solution is used to treat systemic hypertension in cats, a common problem in older cats. It was created to make it easier for cat owners and veterinarians to manage feline hypertension. SEMINTRA is the only FDA-approved treatment for feline hypertension in an easy-to-administrate formulation.

In October 2018, Cipla received approval from the United States FDA to market Metoprolol tablets. These tablets are used to treat hypertension and other cardiac conditions. Extended-release metoprolol succinate tablets treat hypertension, lower blood pressure, and Angina Pectoris.

In September 2018, Sun Pharmaceutical Industries Ltd.'s New Drug Application (NDA) for XELPROSTM 0.005 percent was approved by the USFDA. It aids in reducing elevated intraocular pressure in patients suffering from open-angle glaucoma or ocular hypertension. Sun Pharma's Halol facility approved.

Abbott Laboratories

Overview:

Abbott Laboratories (Abbott) is a company that discovers, develops, manufactures, and sells a wide range of healthcare products. The business is divided into four divisions: established pharmaceutical products, diagnostic products, nutritional products, and medical devices. Its products include rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, diabetic care products, and neuromodulation devices to manage chronic pain and movement disorders.

Product Portfolio:

Telmi 40: Telmi 40 Tablet is a prescription medication used to treat high blood pressure and heart failure. Lowering blood pressure helps to prevent heart attacks and strokes in the future. This medication is also effective in preserving kidney function in diabetic patients. Telmi 40 Tablet can be used alone or in combination with other medications. It can be taken with or without food at any time of day or night. To get the most out of it, try to take it simultaneously every day. Even if you feel fine or your blood pressure is under control, it is critical to take it regularly.

Why Purchase the Report?

Visualize the composition of the global telmisartan market segmentation by indication, composition, distribution channel, and region highlighting the key commercial assets and players.

Identify commercial opportunities in the global telmisartan market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global telmisartan market-level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global telmisartan market report would provide access to an approximately 40+ market data table, 45+ figures, and in the range of 180-200 (approximate) pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers